Priavoid to Present Initial Phase 2 Safety Data for Alzheimer‘s and Preclinical PoC for Parkinson‘s Programs at AD/PD™ 2026
Dusseldorf, Germany, March 5, 2026 - Priavoid GmbH (“Priavoid”) today announced it will present promising initial safety data from the ongoing Phase 2 trial (PRImus-AD, NCT06182085) evaluating its lead candidate PRI-002 in Alzheimer’s disease (AD), as well as preclinical proof-of-concept data for its candidate PRI-101 in alpha-synucleinopathy models like Parkinson’s disease (PD) at the upcoming AD/PD™ 2026 International Conference, taking place from March 17-21, 2026 in Copenhagen, Denmark. Both candidates are based on Priavoid’s proprietary development platform and represent a novel class of orally available all-d-peptide therapeutics designed to detangle neurotoxic oligomer species to inhibit and reverse disease-specific protein aggregation in neurodegenerative disorders.
Initial Phase 2 safety data for PRI-002, which targets amyloid-beta (Aβ) oligomers, will be outlined in an oral presentation by Priavoid’s Chief Science Officer, Prof. Dr. Dieter Willbold. The results indicate a favorable safety and tolerability profile, particularly regarding Amyloid-Related Imaging Abnormalities (ARIA). Following review of relevant safety data, the Drug Safety and Monitoring Board (DSMB) recommended continuing the trial without further ARIA monitoring.
The preclinical proof-of-concept data for PRI-101, a candidate designed to target alpha-synuclein (α-syn) aggregates, will be shared as a poster presentation and include encouraging efficacy data in several in vitro and in vivo PD models.
Priavoid will also present additional posters, including updates from its discovery-stage programs aimed at addressing tauopathies and amyotrophic lateral sclerosis (ALS).
Details of the Talk and Poster Sessions:
Oral Presentation:
Abstract Title: The Abeta Oligomer Disassembling Compound PRI-002 Does Not Cause ARIA in an Ongoing Phase 2 Trial (ID 2426)
Presenting author: Prof. Dr. Dieter Willbold, Priavoid GmbH
Session: 4760 - The App Pathway: From Hidden Fragments to Therapeutic Targets in AD
Date & Time: March 17, 2026, at 3:30 pm CET / 9:30 am EST
Poster:
Abstract Title: #514: Disassembly of α-Synuclein Aggregates by the All-d-Peptide PRI-101: Preclinical Efficacy In Vitro and In Vivo
Presenting author: Dr. Marc Sevenich, Priavoid GmbH
Date & Time: March 19, 2026, 1:50 pm CET until March 21, 2026, 5 pm CET
Poster board number: SHIFT 02-152
Details for additional poster presentations at AD/PD 2026 can be found here.
The PRImus-AD trial is funded by PRInnovation GmbH, affiliate to The Federal Agency for Breakthrough Innovation – SPRIND GmbH.
About Priavoid
Priavoid’s novel class of orally available all-d-peptide therapeutics detangle neurotoxic oligomer species to inhibit and reverse disease-specific protein aggregation in neurodegenerative disorders. We aim to establish clinical proof-of-concept through our lead program, PRI-002, which will complete a Phase 2 trial in Alzheimer’s disease in 2026. Priavoid has built a focused pipeline of detangler compounds that are non-immunogenic and reach their oligomer targets in the brain and inside the affected cells. Our goal is to develop disease-modifying therapies that address the underlying biology of neurodegeneration and drive meaningful clinical benefit for patients.
Contacts:
Priavoid GmbH
Email: media@priavoid.com
Media Requests
Trophic Communications
Anja Heuer and Marie Weickert, PhD
Phone: +49 151 106 199 05
Email: priavoid@trophic.eu
© Copyright Globe Newswire, Inc. All rights reserved. The information contained in this news report may not be published, broadcast or otherwise distributed without the prior written authority of Globe Newswire, Inc.
